Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: Today's therapy of choice
- 31 December 1988
- journal article
- clinical trial
- Published by Elsevier in Journal of Steroid Biochemistry
- Vol. 30 (1-6), 107-117
- https://doi.org/10.1016/0022-4731(88)90083-0
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamideThe Prostate, 1987
- A wide range of sensitivities to androgens develops in cloned shionogi mouse mammary tumor cellsThe Prostate, 1986
- Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.BMJ, 1985
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: Can estrogen treatment increase androgen receptor content?The Journal of Steroid Biochemistry and Molecular Biology, 1983
- Regulation and compartmentalization ofandrogens in rat prostate and muscleJournal of Steroid Biochemistry, 1983
- Cardiovascular Complications in the Treatment of Prostatic CarcinomaBritish Journal of Urology, 1981
- Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent issues in the ratMolecular and Cellular Endocrinology, 1981
- Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol.Journal of Clinical Investigation, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958